Biotech News

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences (CLRB)Cellectar Biosciences2026-06-25 13:46 ESTClinical readout

CLRB (CLRB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is clrb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

CLRBCellectar Biosciences2026-06-25 13:46 EST

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

View all latest news

Cellectar Biosciences

Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CLRBCellectar Biosciences2026-06-26 06:21 EST

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

CLRBCellectar Biosciences2026-06-26 06:21 EST

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CLRBCellectar Biosciences2026-06-26 06:21 EST

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

CLRBCellectar Biosciences2026-06-26 06:21 EST

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

CLRBCellectar Biosciences2026-06-26 06:21 EST

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States